Wellington Management Group
CCCC icon

Wellington Management Group’s C4 Therapeutics CCCC Stock Holding History

Wellington Management Group’s Portfolio CCCC Stock Details CCCC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-283,705
Closed -$1.02M – 1958
2024
Q4 		$1.02M Sell
283,705
-2,336
-0.8% -$11.6K ﹤0.01% 1716
2024
Q3 		$1.63M Buy
286,041
+56,696
+25% +$341K ﹤0.01% 1596
2024
Q2 		$1.06M Buy
229,345
+32,236
+16% +$192K ﹤0.01% 1658
2024
Q1 		$1.61M Buy
+197,109
New +$1.53M ﹤0.01% 1574
2023
Q2 		– Sell
-124,810
Closed -$392K – 1833
2023
Q1 		$392K Sell
124,810
-9,971
-7% -$58.7K ﹤0.01% 1874
2022
Q4 		$795K Buy
134,781
+67,177
+99% +$557K ﹤0.01% 1691
2022
Q3 		$593K Buy
+67,604
New +$702K ﹤0.01% 1753

Other funds holding CCCC

LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SC
Samlyn Capital New York $5.86B AUM 36.3% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Wellington Management Group's CCCC Position: Q1 2025 in Review

Wellington Management Group sold out of C4 Therapeutics (CCCC) in Q1 2025, closing a stake of 283,705 shares — an estimated $1.02M sold.

Wellington Management Group first reported a position in CCCC in Q3 2022 and held it in 7 quarters. The position peaked at $1.63M in Q3 2024. 114 funds tracked by Wall St. Rank hold CCCC as of Q1 2025.

  • Wellington Management Group reported no remaining C4 Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Wellington Management Group sold 283,705 C4 Therapeutics shares in Q1 2025, an estimated $1.02M.
  • Wellington Management Group first reported a position in C4 Therapeutics in Q3 2022 and held it in 7 quarters.
  • Wellington Management Group's C4 Therapeutics position peaked at $1.63M in Q3 2024.
  • 114 funds tracked by Wall St. Rank held C4 Therapeutics as of Q1 2025.

Based on Wellington Management Group's 13F filing for Q1 2025, filed 13 May 2025.